FDA asks Teva for more Treanda data Globes The company added that Treanda remains available and is a safe and an effective treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing ... |
